Dashboard
Manage Tickers

ALZN Alzamend Neuro, Inc.

Nasdaq alzamend.com


$ 2.41 $ 0.08 (3.45 %)    

Tuesday, 21-Oct-2025 15:59:52 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 610.13 $ -0.12 (-0.02 %)
DIA $ 469.20 $ 2.06 (0.44 %)
SPY $ 670.74 $ -0.23 (-0.03 %)
TLT $ 91.98 $ 0.03 (0.03 %)
GLD $ 379.00 $ -8.85 (-2.29 %)
$ 2.35
$ 2.32
$ 2.35 x 10
$ 2.45 x 4,334
$ 2.37 - $ 2.40
$ 2.06 - $ 15.66
77,343
na
7.38M
$ 0.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 09-10-2025 07-31-2025 10-Q
2 07-22-2025 04-30-2025 10-K
3 03-10-2025 01-31-2025 10-Q
4 12-11-2024 10-31-2024 10-Q
5 09-11-2024 07-31-2024 10-Q
6 07-30-2024 04-30-2024 10-K
7 03-25-2024 01-31-2024 10-Q
8 12-15-2023 10-31-2023 10-Q
9 09-13-2023 07-31-2023 10-Q
10 07-27-2023 04-30-2023 10-K
11 03-15-2023 01-31-2023 10-Q
12 12-12-2022 10-31-2022 10-Q
13 09-13-2022 07-31-2022 10-Q
14 07-19-2022 04-30-2022 10-K
15 03-15-2022 01-31-2022 10-Q
16 12-13-2021 10-31-2021 10-Q
17 09-13-2021 07-31-2021 10-Q
18 07-29-2021 04-30-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ascendiant-capital-maintains-buy-on-alzamend-neuro-lowers-price-target-to-42
Ascendiant Capital Maintains Buy on Alzame...
09/25/2025 12:02:01

Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ: ALZN) with a Buy and lowers the price target from $4...

alzamend-neuro-q1-eps-128-misses-069-estimate
Alzamend Neuro Q1 EPS $(1.28) Misses $(0.6...
09/10/2025 20:41:57

Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(0....

hewlett-packard-enterprise-to-rally-around-33-here-are-10-top-analyst-forecasts-for-thursday
Hewlett Packard Enterprise To Rally Around...
08/21/2025 12:19:31

ascendiant-capital-maintains-buy-on-alzamend-neuro-lowers-price-target-to-45
Ascendiant Capital Maintains Buy on Alzame...
08/21/2025 09:32:19

Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and lowers the price target from $18...

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
05/30/2025 17:06:00

alzamend-neuro-alzn-stock-surges-on-al001-phase-ii-trial-milestone
Alzamend Neuro (ALZN) Stock Surges On AL00...
05/29/2025 17:53:10

Alzamend Neuro shares surged after dosing the first patient in its AL001 Phase II trial. This novel lithium formulation aims fo...

crude-oil-falls-over-1-best-buy-reports-downbeat-results
Crude Oil Falls Over 1%; Best Buy Reports ...
05/29/2025 17:13:42

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
05/29/2025 17:07:05

nasdaq-gains-over-1-nvidia-posts-strong-revenue
Nasdaq Gains Over 1%; Nvidia Posts Strong ...
05/29/2025 13:55:20

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
05/29/2025 12:07:57

alzamend-neuro-doses-first-patient-in-phase-ii-clinical-trial-of-al001
Alzamend Neuro Doses First Patient In Phas...
05/29/2025 12:03:34

alzamend-neuro-enrolls-first-patient-of-first-phase-ii-clinical-study-of-al001-in-healthy-human-subjects-topline-data-expected-by-year-end
Alzamend Neuro Enrolls First Patient Of Fi...
05/19/2025 12:02:29

Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted fo...

alzamend-neuro-announces-1-for-9-reverse-stock-split
Alzamend Neuro Announces 1-For-9 Reverse S...
05/08/2025 12:07:41

alzamend-neuro-announces-phase-ii-trial-of-al001-for-alzheimers-in-q4-2025-in-partnership-with-massachusetts-general-hospital
Alzamend Neuro Announces Phase II Trial Of...
03/25/2025 12:03:21

Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel...

alzamend-neuro-plans-initiation-date-of-phase-ii-clinical-trial-of-al001-for-major-depressive-disorder
Alzamend Neuro Plans Initiation Date Of Ph...
03/18/2025 12:07:23

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood an...

ascendiant-capital-maintains-buy-on-alzamend-neuro-lowers-price-target-to-20
Ascendiant Capital Maintains Buy on Alzame...
03/17/2025 11:48:48

Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and lowers the price target from $32...

alzamend-neuro-plans-to-initiate-phase-ii-study-of-al001-in-bipolar-disorder-expected-to-commence-in-q3
Alzamend Neuro Plans To Initiate Phase II ...
03/04/2025 13:12:56

alzamend-neuro-shares-are-trading-higher-after-the-company-announced-the-completion-of-its-head-coil-by-tesla-dynamic-coils-bv
Alzamend Neuro shares are trading higher a...
02/19/2025 13:08:27

alzamend-neuro-to-present-non-clinical-data-update-on-pharmacokinetics-of-al001-a-lithium-salicylatel-proline-co-crystal-as-a-potentially-beneficial-lithium-sparing-treatment-for-bipolar-disorder-type-1-alzheimers-disease-major-depressive-disorder-and-post-traumatic-stress-disorder-at-the-society-of-toxicology-2025-annual-meeting-and-toxexpo
Alzamend Neuro To Present Non-Clinical Dat...
12/18/2024 13:12:59

Presentation Topic is the Pharmacokinetics of AL001, a Lithium Salicylate/L-Proline Co-crystal, as a Potentially Beneficial Lit...

ascendiant-capital-maintains-buy-on-alzamend-neuro-lowers-price-target-to-32
Ascendiant Capital Maintains Buy on Alzame...
12/16/2024 09:25:45

Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and lowers the price target from $35...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION